Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223


Condition: Prostate Cancer Metastatic, Bone Metastases

Study Type: Observational

Clinical Trials Identifier NCT 8-digits: NCT03223727

Sponsor: The Netherlands Cancer Institute

Phase:

Eligibility:

  • Age: minimum 18 Years maximum N/A
  • Gender: Male

Inclusion Criteria:

  • At the physicians discretion
  • Age 18 year and older.
  • Written informed consent

Exclusion Criteria:

  • Previous treatment with Radium-223.
  • Participation in another Radium-223 study.

View trial on ClinicalTrials.gov